1
|
Jensen KT, Nielsen NS, Viana Almeida A, Thøgersen IB, Enghild JJ, Harwood SL. Proteolytic cleavage of the TGFβ co-receptor CD109 changes its conformation, resulting in protease inhibition via activation of its thiol ester, and dissociation from the cell membrane. FEBS J 2024; 291:3169-3190. [PMID: 38587194 DOI: 10.1111/febs.17128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2023] [Revised: 02/14/2024] [Accepted: 03/18/2024] [Indexed: 04/09/2024]
Abstract
The glycosylphosphatidylinositol (GPI)-anchored protein cluster of differentiation 109 (CD109) is expressed on many human cell types and modulates the transforming growth factor β (TGF-β) signaling network. CD109 belongs to the alpha-macroglobulin family of proteins, known for their protease-triggered conformational changes. However, the effect of proteolysis on CD109 and its conformation are unknown. Here, we investigated the interactions of CD109 with proteases. We found that a diverse selection of proteases cleaved peptide bonds within the predicted bait region of CD109, inducing a conformational change that activated the thiol ester of CD109. We show CD109 was able to conjugate proteases with this thiol ester and decrease their activity toward protein substrates, demonstrating that CD109 is a protease inhibitor. We additionally found that CD109 has a unique mechanism whereby its GPI-anchored macroglobulin 8 (MG8) domain dissociates during its conformational change, allowing proteases to release CD109 from the cell surface by a precise mechanism and not unspecific shedding. We conclude that proteolysis of the CD109 bait region affects both its structure and location, and that interactions between CD109 and proteases may be important to understanding its functions, for example, as a TGF-β co-receptor.
Collapse
Affiliation(s)
| | | | - Ana Viana Almeida
- Department of Molecular Biology and Genetics, Aarhus University, Denmark
| | - Ida B Thøgersen
- Department of Molecular Biology and Genetics, Aarhus University, Denmark
| | - Jan J Enghild
- Department of Molecular Biology and Genetics, Aarhus University, Denmark
| | | |
Collapse
|
2
|
Liu Y, Zhang Y, Chen D, Fu Y. Current Status of and Global Trends in Platelet Transfusion Refractoriness From 2004 to 2021: A Bibliometric Analysis. Front Med (Lausanne) 2022; 9:873500. [PMID: 35602482 PMCID: PMC9121734 DOI: 10.3389/fmed.2022.873500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2022] [Accepted: 04/14/2022] [Indexed: 11/13/2022] Open
Abstract
Platelet transfusion refractoriness (PTR) is common in patients with hematology and oncology and is becoming an important barrier in the treatment of thrombocytopenia and hemorrhage. Bibliometrics is an effective method for identifying existing research achievements, important breakthroughs, current research hotspots, and future development trends in any given field. In recent years, research on PTR has received increasing attention, but a bibliometric analysis of this field has not yet been reported. In this study, we applied bibliometrics to analyze the existing literature on PTR research over the past 17 years. On November 1, 2021, we began a publications analysis of PTR research using the Science Citation Index Expanded of the Web of Science Core Collection with collection dates from 2004 to 2021. This research aimed to summarize the state of PTR research using Bibliometrix to identify connections between different elements (i.e., authors, institutions, countries, journals, references, and keywords) using VOS viewer analyses to visualize key topics and trends in PTR research using Cite Space and gCLUTO. The results of all 310 studies showed that the annual number of publications focused on PTR is steadily increasing, with the United States of America and Japan making significant contributions. We noted that the research group led by Dr. Sherrill J. Slichter was prominent in this field, while Estcourt Lise may become the most influential newcomer. Transfusion was the most popular journal, and Blood was the most cited journal. Using various analyses, including co-cited analysis, historiography analysis, citation burst analysis, and factorial analysis, we pointed out and discussed contributing publications. According to occurrence analysis, co-word biclustering analysis, landform map, thematic evolution, and thematic map, we believe that “activation,” “p-selection,” “CD36 deficiency,” “gene-frequencies,” “CD109,” “HPA-1,” and “beta (3) integrin” may become new trends in PTR research. The outcome of our bibliometric analyses has, for the first time, revealed profound insights into the current state and trends in PTR research. The systematic analysis provided by our study clearly demonstrates the field's significant advancements to all researchers who are interested in a quick and comprehensive introduction to the field.
Collapse
Affiliation(s)
- Ying Liu
- Nanfang Hospital, Southern Medical University, Guangzhou, China
- Guangzhou Blood Center, Guangzhou, China
| | - Yufan Zhang
- Department of Plastic and Aesthetic Surgery, Nanfang Hospital of Southern Medical University Guangzhou, Guangzhou, China
| | - Dawei Chen
- Guangzhou Blood Center, Guangzhou, China
| | - Yongshui Fu
- Nanfang Hospital, Southern Medical University, Guangzhou, China
- Guangzhou Blood Center, Guangzhou, China
- *Correspondence: Yongshui Fu
| |
Collapse
|
3
|
Yasumi M, Yokota T, Endo T, Kusakabe S, Koh Y, Sakamoto H, Inoue H, Sudo T, Hosen N, Karasuno T. Relationship between donor-specific HPA-15 antibodies and poor graft function in HPA-15 mismatched cord blood transplantation. Int J Hematol 2022; 115:753-758. [PMID: 35028883 DOI: 10.1007/s12185-022-03286-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2021] [Revised: 01/06/2022] [Accepted: 01/06/2022] [Indexed: 01/05/2023]
Abstract
Poor graft function (PGF) is a fatal complication following hematopoietic stem cell transplantation and is influenced by multiple factors, such as donor-specific anti-HLA antibodies, a poor infused CD34+ cell count, and the donor source. Alloantibodies against human platelet antigen 15 (HPA-15) recognize platelet membrane glycoprotein CD109, which is expressed not only on platelets, but also on megakaryocytes and specific hematopoietic stem cells. HPA-15 antibodies are known to induce platelet transfusion refractoriness and neonatal alloimmune thrombocytopenia, but their effects on graft function following hematopoietic stem cell transplantation remain unknown. We encountered a case of HPA-15 mismatched cord blood transplantation with a high HPA-15b antibody titer. Prolonged PGF and megakaryocyte aplasia with sustained high-titer HPA-15b antibodies were attenuated by rituximab therapy, and rapid recovery of hematopoiesis was achieved. HPA-15-compatible platelet transfusions were highly effective for platelet recovery. Methylcellulose assays and megakaryocyte cultures revealed that patient serum inhibited in vitro hematopoietic development from patient bone marrow cells. These results suggest that HPA-15 antibodies might be a cause of PGF and that reducing the HPA-15 antibody titer might improve graft function in HPA-15 mismatched transplantation.
Collapse
Affiliation(s)
- Masato Yasumi
- Department of Hematology, Rinku General Medical Center, 2-3 Ourai-Kita, Rinku, Izumisano, Osaka, 598-8577, Japan.
| | - Takafumi Yokota
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Takaya Endo
- Department of Hematology, Rinku General Medical Center, 2-3 Ourai-Kita, Rinku, Izumisano, Osaka, 598-8577, Japan
| | - Shinsuke Kusakabe
- Department of Hematology, Rinku General Medical Center, 2-3 Ourai-Kita, Rinku, Izumisano, Osaka, 598-8577, Japan.,Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Yangsook Koh
- Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan
| | - Hiroe Sakamoto
- Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan
| | - Hiroko Inoue
- Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan
| | - Takao Sudo
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Naoki Hosen
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Takahiro Karasuno
- Department of Hematology, Rinku General Medical Center, 2-3 Ourai-Kita, Rinku, Izumisano, Osaka, 598-8577, Japan
| |
Collapse
|
4
|
Kuroishi A, Takihara Y, Hirayama F. Current understanding and future perspectives for anti-human platelet antigen-15 antibodies in patients with alloimmune thrombocytopenia: History, laboratory testing, and clinical impact. Transfusion 2022; 62:1128-1141. [PMID: 35266549 DOI: 10.1111/trf.16845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2021] [Revised: 02/02/2022] [Accepted: 02/11/2022] [Indexed: 11/30/2022]
Affiliation(s)
- Ayumu Kuroishi
- Laboratory, Japanese Red Cross Kinki Block Blood Center, Ibaraki-shi, Osaka, Japan
| | | | - Fumiya Hirayama
- Japanese Red Cross Kinki Block Blood Center, Ibaraki-shi, Osaka, Japan
| |
Collapse
|
5
|
Sharp G, Poles A, Studholme L. A first WHO reference reagent for the detection of anti-human platelet antigen-15b. Vox Sang 2021; 117:275-281. [PMID: 34164825 PMCID: PMC9292896 DOI: 10.1111/vox.13167] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 05/26/2021] [Accepted: 06/02/2021] [Indexed: 11/29/2022]
Abstract
Background and Objectives Alloantibodies to human platelet antigen‐15b (anti‐HPA‐15b) have been detected in mothers with foetal–neonatal alloimmune thrombocytopenia and in multiply transfused patients. Assays used to detect this antibody, which aids in disease diagnosis, can be unreliable and vary in sensitivity. The objective was to generate a stable, lyophilized anti‐HPA‐15b preparation and evaluate its suitability as a World Health Organization (WHO) reference reagent for use in the quality control of platelet alloantibody detection assays. Results from an international collaborative study to evaluate the preparation were used to assign a minimum potency at which laboratories can be expected to detect the antibody. Materials and Methods Recalcified plasma containing anti‐HPA‐15b was aliquotted, lyophilized and coded 18/220. Twenty‐five laboratories in 16 countries tested doubling dilutions of the reconstituted material in glycoprotein‐specific assays such as the monoclonal antibody–specific immobilization of platelet antigen assay and reported the last positive (or endpoint) dilution. Results Twenty‐four laboratories (96%) detected antibodies with HPA‐15b specificity in preparation 18/220. Reported endpoint dilutions were normally distributed with a modal dilution of 1 in 16 and ranged from 1 in 2 to 1 in 128. Only two laboratories (8%) failed to detect anti‐HPA‐15b at 1 in 8 dilution. Conclusions When diluted 1 in 8, most laboratories detected anti‐HPA‐15b in preparation 18/220 using HPA‐15bb platelets but not with HPA‐15aa platelets. The participants agreed this to be an appropriate dilution for assignment as the minimum potency. In October 2020, the WHO Expert Committee on Biological Standardization approved 18/220 as an International Reference Reagent.
Collapse
Affiliation(s)
- Giles Sharp
- Biotherapeutics Division, National Institute for Biological Standards and Control (NIBSC), Potters Bar, UK
| | - Anthony Poles
- Histocompatibility and Immunogenetics, NHSBT, Filton, UK
| | - Lucy Studholme
- Biotherapeutics Division, National Institute for Biological Standards and Control (NIBSC), Potters Bar, UK
| |
Collapse
|
6
|
Inoue H, Sakamoto R, Nishimiya H, Sakamoto H, Terasu S, Aminaka R, Koh Y, Takihara Y, Hirayama F, Kuroishi A. Minor impact of patient alloantibodies against human platelet antigen (HPA)-15 in the effectiveness of platelet transfusion: A pilot study. Transfusion 2020; 61:738-743. [PMID: 33166416 DOI: 10.1111/trf.16181] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2020] [Revised: 10/12/2020] [Accepted: 10/12/2020] [Indexed: 12/25/2022]
Abstract
BACKGROUND Alloantibodies against human platelet antigen (HPA)-15 are sometimes detected in patients with platelet transfusion refractoriness (PTR); however, little is known about their impact on PTR. STUDY DESIGN AND METHODS Two patients who possessed HPA-15 alloantibodies (Patient 1, anti-HPA-15b; Patient 2, anti-HPA-15a) and human leukocyte antigen (HLA) antibodies were enrolled. The efficacy of HPA-15-compatible vs -incompatible platelet transfusion was compared by focusing on ABO- and HLA-matched transfusions on the basis of the 24-hour corrected count increment (CCI-24 hours) for platelets. The titers of HPA-15 antibodies in the patients' sera were also monitored. RESULTS The patients received 71 and 12 ABO-compatible, HLA-matched platelet transfusions, respectively, during the monitoring periods. Among these transfusions, CCI-24 hours could be calculated in 27 and 10 transfusions, respectively, and the HPA-15 genotype of the donors was determined. There were no significant differences in the CCI-24 hours between the HPA-15 compatible and incompatible transfusions in both patients (P = .30 and .56, respectively, Mann-Whitney U test). There was no significant change in the HPA-15b antibody titer in Patient 1 during the monitoring period, while the HPA-15a antibody level in Patient 2 was undetectable at the end of the monitoring period, although the titer was low at the beginning. CONCLUSION The efficacy of HPA-15-incompatible platelet transfusions was not necessarily inferior to that of HPA-15 compatible ones. Although the case number was limited, our results suggest that HPA-15 antibodies do not have a significant impact on the effects of platelet transfusion.
Collapse
Affiliation(s)
- Hiroko Inoue
- Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan
| | - Rumi Sakamoto
- Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan
| | | | - Hiroe Sakamoto
- Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan
| | - Shota Terasu
- Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan
| | - Ryota Aminaka
- Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan
| | - Yangsook Koh
- Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan
| | | | | | - Ayumu Kuroishi
- Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan
| |
Collapse
|
7
|
Blanco S, Vega LC, Carrizo LH, Culasso JM, Gallego SV. Fetal and neonatal alloimmune thrombocytopenia: a late or missed diagnosis disease in fetal and perinatal health-care settings. J Matern Fetal Neonatal Med 2020; 35:263-268. [PMID: 31973628 DOI: 10.1080/14767058.2020.1716713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Introduction: Even though Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) has been recognized as the main cause of primary hemorrhagic morbidity and mortality in fetuses and newborns, screening programs to detect pregnancies at risk have not yet been implemented in any country. Moreover, in spite of increased concerns about maternal, fetal and neonatal health care in general, this potentially lethal disease is still underdiagnosed. The aim of this report is to highlight the importance of considering FNAIT in fetal and perinatal health-care settings and show the usefulness of molecular tools in early diagnosis of this clinical entity.Methods: DNA was extracted from whole blood from parents and newborns; genotyping was performed by in house PCR using sequence-specific primers for typing Human Platelet Antigens (HPA)-1 to -6, -9, and -15, and with commercial HPA-TYPE (BAG HealthCare, Lich, Germany). Anti-HPA antibodies in the maternal serum were detected by the Monoclonal Antibody Solid Phase Platelet antibody Test (MASPAT). Chloroquine-treated platelets were used for the discrimination of platelet-specific antibodies from anti-HLA antibodies.Results: Patients 1 and 2 had severe thrombocytopenia due to incompatibility in HPA-1 and HPA-15, respectively. The third case was a thrombocytopenic neonate with severe bleeding complications other than ICH and in whom differential diagnosis between FNAIT and Von Willebrand congenital disease was necessary; incompatibility in HPA-15 was also demonstrated. Case 4 represents a missed diagnostic opportunity.Conclusion: This is the first report of FNAIT cases confirmed by molecular evidence and anti-HPA antibodies detection in Argentina. This report reinforces the relevance of early diagnosis of this clinical entity. Since the delay in FNAIT diagnosis could lead to severe consequences in the fetus and neonates, strategies to approach maternal, fetal, and perinatal health, as well as prevention policies aimed to reduce fetal and neonatal morbidity and mortality should focus on implementing programs to identify high-risk pregnancies and thus reduce thrombocytopenia-related complications in fetuses and newborns.
Collapse
Affiliation(s)
- Sebastián Blanco
- Fundación Banco Central de Sangre, Córdoba, Argentina.,Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina
| | - Laura C Vega
- Servicio de Hemoterapia e Inmunohematología, Hospital Materno-Provincial Dr. Raúl Felipe Lucini, Córdoba, Argentina
| | - Luis H Carrizo
- Fundación Banco Central de Sangre, Córdoba, Argentina.,Servicio de Hemoterapia e Inmunohematología, Hospital Materno-Provincial Dr. Raúl Felipe Lucini, Córdoba, Argentina.,Servicio de Hemoterapia, Clínica y Maternidad del Sol, Córdoba, Argentina
| | - Jorge M Culasso
- Servicio de Hemoterapia e Inmunohematología, Hospital Materno-Provincial Dr. Raúl Felipe Lucini, Córdoba, Argentina
| | - Sandra V Gallego
- Fundación Banco Central de Sangre, Córdoba, Argentina.,Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina
| |
Collapse
|
8
|
Koh Y, Nishimiya H, Inoue H, Kishigami A, Tsuji Y, Sakamoto R, Hirayama F, Kuroishi A. A novel simple assay system for the detection of human platelet antigen 15 (HPA‐15) alloantibodies based on three techniques: an HPA‐15 expressing cell line, a monoclonal antibody‐specific antigen‐capture method and mixed‐passive haemagglutination. Vox Sang 2019; 115:202-206. [DOI: 10.1111/vox.12843] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2019] [Revised: 08/03/2019] [Accepted: 08/12/2019] [Indexed: 11/27/2022]
Affiliation(s)
- Yangsook Koh
- Japanese Red Cross Kinki Block Blood Centre Osaka Japan
| | | | - Hiroko Inoue
- Japanese Red Cross Kinki Block Blood Centre Osaka Japan
| | | | - Yukari Tsuji
- Japanese Red Cross Kinki Block Blood Centre Osaka Japan
| | - Rumi Sakamoto
- Japanese Red Cross Kinki Block Blood Centre Osaka Japan
| | | | | |
Collapse
|
9
|
Carmo Corrêa DED, Maria Ayo C, Laguila Visentainer JE, Ambrosio-Albuquerque EP, Guimarães Reis P, Brandão de Mattos CC, Bestetti RB, de Mattos LC, Maria Sell A. Human platelet antigen polymorphisms and the risk of chronic Chagas disease cardiomyopathy. Platelets 2019; 31:272-275. [PMID: 31538834 DOI: 10.1080/09537104.2019.1667496] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Human platelet antigen (HPA) polymorphisms are considered to be a risk factor for cardiac and vascular diseases, but the role of HPA in chronic Chagas disease cardiomyopathy (CCC) is not available. Therefore, the aim of this study was to investigate the association of HPA polymorphisms, HPA-1, HPA-2, HPA-3, HPA-5 and HPA-15, in the severity of left ventricular systolic dysfunction (LVSD) in CCC patients. For this, 229 CCC patients were separated into three groups: without LVSD, mild/moderate LVSD and severe LVSD. PCR-SSP was performed for HPA genotyping and the risk was assessed using SNPStats software. HPA-1 allele and genotype frequencies were lower in mild/moderate LVSD patients compared to other groups, without statistical significance. After stratified analyzes, the HPA-3a/3b genotype frequency was lower in women with severe LVSD compared to those without LVSD (OR:0.29; 95% CI: 0.10-0.84). In conclusion, HPA-3 variant could be a protection factor for CCC in the female patients.
Collapse
Affiliation(s)
- Deborah Elzita do Carmo Corrêa
- Post Graduation Program in Bioscience and Physiopathogy, Department of Clinical Analysis and Biomedicine, Maringá State University, Maringá, Paraná, Brazil
| | - Christiane Maria Ayo
- Department of Molecular Biology, Faculdade de Medicina de São José do Rio Preto, São Jose do Rio Preto, São Paulo, Brazil
| | - Jeane Eliete Laguila Visentainer
- Post Graduation Program in Bioscience and Physiopathogy, Department of Clinical Analysis and Biomedicine, Maringá State University, Maringá, Paraná, Brazil
| | | | - Pâmela Guimarães Reis
- Post Graduation Program in Bioscience and Physiopathogy, Department of Clinical Analysis and Biomedicine, Maringá State University, Maringá, Paraná, Brazil
| | | | | | - Luiz Carlos de Mattos
- Department of Molecular Biology, Faculdade de Medicina de São José do Rio Preto, São Jose do Rio Preto, São Paulo, Brazil
| | - Ana Maria Sell
- Post Graduation Program in Bioscience and Physiopathogy, Department of Clinical Analysis and Biomedicine, Maringá State University, Maringá, Paraná, Brazil
| |
Collapse
|
10
|
Mii S, Enomoto A, Shiraki Y, Taki T, Murakumo Y, Takahashi M. CD109: a multifunctional GPI‐anchored protein with key roles in tumor progression and physiological homeostasis. Pathol Int 2019; 69:249-259. [DOI: 10.1111/pin.12798] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2019] [Accepted: 03/13/2019] [Indexed: 12/13/2022]
Affiliation(s)
- Shinji Mii
- Department of PathologyNagoya University Graduate School of Medicine Nagoya Japan
| | - Atsushi Enomoto
- Department of PathologyNagoya University Graduate School of Medicine Nagoya Japan
| | - Yukihiro Shiraki
- Department of PathologyNagoya University Graduate School of Medicine Nagoya Japan
- Division of Molecular Pathology, Center for Neurological Disease and CancerNagoya University Graduate School of Medicine Nagoya Japan
| | - Tetsuro Taki
- Department of PathologyNagoya University Graduate School of Medicine Nagoya Japan
| | - Yoshiki Murakumo
- Department of PathologyKitasato University School of Medicine Sagamihara Japan
| | - Masahide Takahashi
- Department of PathologyNagoya University Graduate School of Medicine Nagoya Japan
- Division of Molecular Pathology, Center for Neurological Disease and CancerNagoya University Graduate School of Medicine Nagoya Japan
| |
Collapse
|
11
|
Le BT, Hughes Q, Rakesh S, Baker R, Jørgensen PT, Wengel J, Veedu RN. Unlocked nucleic acid modified primer-based enzymatic polymerization assay: towards allele-specific genotype detection of human platelet antigens. RSC Adv 2018; 8:32770-32774. [PMID: 35547719 PMCID: PMC9086379 DOI: 10.1039/c8ra06050a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2018] [Accepted: 08/24/2018] [Indexed: 12/12/2022] Open
Abstract
Accurate detection of single nucleotide polymorphisms (SNPs) is paramount for the appropriate therapeutic intervention of debilitating diseases associated with SNPs. However, in some cases current nucleic acid probes fail to detect allele-specific mutations, for example, human platelet antigens, HPA-15a (TCC) and HPA-15b (TAC) alleles associated with neonatal alloimmune thrombocytopenia. Towards this, it is necessary to develop a novel assay for detection of allele-specific mutations. In this study, we investigated the potential of unlocked nucleic acid (UNA)-modified primers in SNP detection utilising an enzymatic polymerisation-based approach. Our results of primer extension and asymmetric polymerase chain reaction by KOD XL DNA polymerase revealed that UNA-modified primers achieved excellent allele-specificity in discriminating the human platelet antigen DNA template, whereas the DNA control primers were not able to differentiate between the normal and mutant alleles, demonstrating the scope of this novel UNA-based enzymatic approach as a robust methodology for efficient detection of allele-specific mismatches. Although further evaluation is required for other disease conditions, we firmly believe that our findings offer a great promise for the diagnosis of neonatal alloimmune thrombocytopenia and other SNP-related diseases.
Collapse
Affiliation(s)
- Bao T Le
- Centre for Comparative Genomics, Murdoch University Perth Australia-6150
- Perron Institute for Neurological and Translational Science Perth Australia-6009
| | | | | | - Ross Baker
- Perth Blood Institute Nedlands Perth WA Australia
| | - Per T Jørgensen
- BioNEC, Department of Physics, Chemistry and Pharmacy, University of Southern Denmark Odense M 5231 Denmark
| | - Jesper Wengel
- BioNEC, Department of Physics, Chemistry and Pharmacy, University of Southern Denmark Odense M 5231 Denmark
| | - Rakesh N Veedu
- Centre for Comparative Genomics, Murdoch University Perth Australia-6150
- Perron Institute for Neurological and Translational Science Perth Australia-6009
- BioNEC, Department of Physics, Chemistry and Pharmacy, University of Southern Denmark Odense M 5231 Denmark
| |
Collapse
|
12
|
Lin M, Xu X, Lee HL, Liang DC, Santoso S. Fetal/neonatal alloimmune thrombocytopenia due to anti-CD36 antibodies: antibody evaluations by CD36-transfected cell lines. Transfusion 2017; 58:189-195. [PMID: 29030871 DOI: 10.1111/trf.14369] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2017] [Revised: 08/28/2017] [Accepted: 08/28/2017] [Indexed: 11/29/2022]
Abstract
BACKGROUND Isoantibodies against CD36 (platelet glycoprotein 4), developed in Type I CD36-deficient mothers are frequently reported as the cause of fetal/neonatal alloimmune thrombocytopenia in the Asian population. Therefore, further detailed characterization of anti-CD36-mediated fetal/neonatal alloimmune thrombocytopenia is warranted. Here, we report the characterization of a patient with fetal/neonatal alloimmune thrombocytopenia in a Taiwanese family caused by anti-CD36 isoantibodies using a novel antigen-capture method. STUDY DESIGN AND METHODS Platelets and monocytes were analyzed for CD36 expression by flow cytometry. Sequencing analysis of the CD36 gene was performed to identify the mutation underlying the CD36 deficiency. Stable transfected human embryonic kidney HEK293 cells expressing recombinant CD36 were established. These cells were used for the characterization of anti-CD36 isoantibodies by flow cytometry, immunoprecipitation, and antigen-capture assay. RESULTS Flow cytometry analysis revealed a total absence of CD36 on both platelets and monocytes of the mother (Type I CD36-deficient) caused by heterozygous deletions of the CD36 gene (332_333delCA and c.1254 + 6_1254 + 11delTATTTG). Analysis of maternal serum with CD36-transfected HEK293 cells by flow cytometry, immunoprecipitation, and antigen-capture assay demonstrated the presence of anti-CD36 isoantibodies in maternal serum. Interestingly, this antibody could not be detected by the monoclonal antibody immobilization of platelet antigens assay when anti-CD36 monoclonal antibody (clone FA6-152) was used as the capture antibody. CONCLUSION This case reemphasizes the role of anti-CD36 isoantibodies on the pathomechanism of fetal/neonatal alloimmune thrombocytopenia. The fact that the monoclonal antibody immobilization of platelet antigens assay does not seem to be reliable for the identification of all anti-CD36 antibodies indicates that screening of anti-CD36 isoantibodies by a monoclonal antibody-independent method, as presented here, should be considered.
Collapse
Affiliation(s)
- Marie Lin
- Department of Medical Research, Mackay Memorial Hospital, Tamsui, New Taipei City, Taiwan
| | - Xiuzhang Xu
- Institute for Clinical Immunology and Transfusion Medicine, Justus-Liebig University Giessen, Giessen, Germany
| | - Hui-Lin Lee
- Department of Medical Research, Mackay Memorial Hospital, Tamsui, New Taipei City, Taiwan
| | - Der-Cheng Liang
- Department of Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan
| | - Sentot Santoso
- Institute for Clinical Immunology and Transfusion Medicine, Justus-Liebig University Giessen, Giessen, Germany
| |
Collapse
|
13
|
Affiliation(s)
- R. Kapur
- Division of Hematology and Transfusion Medicine; Lund University; Lund Sweden
| | - J. W. Semple
- Division of Hematology and Transfusion Medicine; Lund University; Lund Sweden
- Keenan Research Centre for Biomedical Science; St. Michael's Hospital; Toronto ON Canada
- Departments of Pharmacology, Medicine and Laboratory Medicine and Pathobiology; University of Toronto; Toronto ON Canada
| |
Collapse
|
14
|
Thude H, Bischoff W, Sterneck M, Marget M, Nashan B, Koch M. Polymorphisms of the human platelet antigen-1, -2, -3, -5, and -15 systems and acute cellular liver transplant rejection. Hum Immunol 2017; 78:534-539. [PMID: 28705752 DOI: 10.1016/j.humimm.2017.07.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2017] [Revised: 07/05/2017] [Accepted: 07/07/2017] [Indexed: 12/14/2022]
Abstract
The human platelet antigen (HPA)-1, -2, -3, -5, and -15 systems are characterized as polymorphic alloantigens expressed on platelets and endothelial cells. In this retrospective study, we investigated, whether HPA-1, -2, -3, -5, and -15 incompatibilities are associated with acute cellular liver transplant rejection. A total of 96 Caucasian liver transplant recipients and corresponding donors were analyzed, 43 with biopsy proven acute cellular rejection (BPAR) and 53 without acute cellular rejection (No-BPAR). Polymorphisms of mentioned HPA systems were determined by polymerase chain reaction-sequence specific primers (PCR-SSP). Our data demonstrate that acute cellular rejection episodes were associated with HPA-3 incompatibility (58% HPA-3 incompatibility in BPAR group vs. 32% HPA-3 incompatibility in No-BPAR group, p=0.013). Furthermore, the frequency of HPA-3bb genotype was significantly higher in BPAR recipients as compared to No-BPAR recipients (30% vs 6%, p=0.002). On the other hand, there was no association between acute cellular rejection and the other tested HPA systems. We conclude that in the Caucasian population the HPA-3 system confers susceptibility to acute cellular rejection after liver transplantation.
Collapse
Affiliation(s)
- Hansjörg Thude
- University Medical Center Hamburg-Eppendorf, Department of Hepatobiliary and Transplant Surgery, Martinistraße 52, 20246 Hamburg, Germany.
| | - Wiebke Bischoff
- University Medical Center Hamburg-Eppendorf, Department of Hepatobiliary and Transplant Surgery, Martinistraße 52, 20246 Hamburg, Germany
| | - Martina Sterneck
- University Medical Center Hamburg-Eppendorf, Department of Hepatobiliary and Transplant Surgery, Martinistraße 52, 20246 Hamburg, Germany
| | - Matthias Marget
- University Medical Center Hamburg-Eppendorf, Institute for Transfusion Medicine, Martinistraße 52, 20246 Hamburg, Germany
| | - Björn Nashan
- University Medical Center Hamburg-Eppendorf, Department of Hepatobiliary and Transplant Surgery, Martinistraße 52, 20246 Hamburg, Germany; University Medical Center Hamburg-Eppendorf, Institute for Transfusion Medicine, Martinistraße 52, 20246 Hamburg, Germany
| | - Martina Koch
- University Medical Center Hamburg-Eppendorf, Department of Hepatobiliary and Transplant Surgery, Martinistraße 52, 20246 Hamburg, Germany
| |
Collapse
|
15
|
Tiller H, Husebekk A, Ahlen MT, Stuge TB, Skogen B. Current perspectives on fetal and neonatal alloimmune thrombocytopenia - increasing clinical concerns and new treatment opportunities. Int J Womens Health 2017; 9:223-234. [PMID: 28458583 PMCID: PMC5402885 DOI: 10.2147/ijwh.s90753] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Differences in platelet type between the fetus and the mother can lead to maternal immunization and destruction of the fetal platelets, a condition named fetal and neonatal alloimmune thrombocytopenia (FNAIT). FNAIT is reported to occur in ~1 per 1,000 live born neonates. The major risk is intracranial hemorrhage in the fetus or newborn, which is associated with severe neurological complications or death. Since no countries have yet implemented a screening program to detect pregnancies at risk, the diagnosis is typically established after the birth of a child with symptoms. Reports on broader clinical impact have increased clinical concern and awareness. Along with new treatment options for FNAIT, the debate around antenatal screening to detect pregnancies at risk of FNAIT has been revitalized.
Collapse
Affiliation(s)
- Heidi Tiller
- Immunology Research Group, Faculty of Health Sciences, UiT, The Arctic University of Norway
| | - Anne Husebekk
- Immunology Research Group, Faculty of Health Sciences, UiT, The Arctic University of Norway
| | | | - Tor B Stuge
- Immunology Research Group, Faculty of Health Sciences, UiT, The Arctic University of Norway
| | - Bjørn Skogen
- Department of Laboratory Medicine, Norwegian National Unit for Platelet Immunology, University Hospital of North Norway, Tromsø, Norway
| |
Collapse
|
16
|
Wu G, Zhou Y, Li L, Zhong Z, Li H, Li H, Yu M, Shen W, Ni H. Platelet Immunology in China: Research and Clinical Applications. Transfus Med Rev 2017; 31:118-125. [DOI: 10.1016/j.tmrv.2016.12.001] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2016] [Revised: 12/01/2016] [Accepted: 12/01/2016] [Indexed: 12/29/2022]
|
17
|
Wikman A, Mörtberg A, Sachs UJ, Santoso S. Report on the 18th Platelet Immunology Workshop of the ISBT 2016. ACTA ACUST UNITED AC 2017. [DOI: 10.1111/voxs.12336] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- A. Wikman
- Department of Clinical Immunology and Transfusion Medicine; Karolinska University Hospital; Stockholm Sweden
| | - A. Mörtberg
- Department of Clinical Immunology and Transfusion Medicine; Karolinska University Hospital; Stockholm Sweden
| | - U. J. Sachs
- Institute for Clinical Immunology and Transfusion Medicine; Justus Liebig University; Giessen Germany
| | - S. Santoso
- Institute for Clinical Immunology and Transfusion Medicine; Justus Liebig University; Giessen Germany
| |
Collapse
|
18
|
Bub CB, Gonçalez AC, Barjas-Castro ML, Sousa LCDM, do Monte SJH, Castro V. The use of a potential novel tool in virtual crossmatching for platelet transfusion in platelet refractoriness. Vox Sang 2015; 110:70-8. [DOI: 10.1111/vox.12315] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2015] [Revised: 06/17/2015] [Accepted: 06/22/2015] [Indexed: 12/01/2022]
Affiliation(s)
- C. B. Bub
- Hematology and Hemotherapy Center; University of Campinas - UNICAMP; Instituto Nacional de Ciência e Tecnologia do Sangue (INCTS); Campinas Brazil
| | - A. C. Gonçalez
- Hematology and Hemotherapy Center; University of Campinas - UNICAMP; Instituto Nacional de Ciência e Tecnologia do Sangue (INCTS); Campinas Brazil
| | - M. L. Barjas-Castro
- Hematology and Hemotherapy Center; University of Campinas - UNICAMP; Instituto Nacional de Ciência e Tecnologia do Sangue (INCTS); Campinas Brazil
| | - L. C. D. M. Sousa
- Immunogenetics and Molecular Biology Laboratory; Federal University of Piauí; Teresina Brazil
| | - S. J. H. do Monte
- Immunogenetics and Molecular Biology Laboratory; Federal University of Piauí; Teresina Brazil
| | - V. Castro
- Hematology and Hemotherapy Center; University of Campinas - UNICAMP; Instituto Nacional de Ciência e Tecnologia do Sangue (INCTS); Campinas Brazil
| |
Collapse
|
19
|
Mangerona CMB, Garcia FB, Moraes-Souza H. Frequency of human platelet antigens (HPA)-1, -2, -5 and -15 in Brazilian blood donors and establishment of a panel of HPA-typed donors. Transfus Med 2015; 25:189-94. [PMID: 26033262 DOI: 10.1111/tme.12210] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2014] [Revised: 04/08/2015] [Accepted: 05/03/2015] [Indexed: 11/30/2022]
Affiliation(s)
- C. M. B. Mangerona
- Discipline of Hematology and Hemotherapy; Universidade Federal do Triângulo Mineiro
| | - F. B. Garcia
- Discipline of Hematology and Hemotherapy; Universidade Federal do Triângulo Mineiro
- Regional Blood Center of Uberaba; HEMOMINAS Foundation; Uberaba Brazil
| | - H. Moraes-Souza
- Discipline of Hematology and Hemotherapy; Universidade Federal do Triângulo Mineiro
- Regional Blood Center of Uberaba; HEMOMINAS Foundation; Uberaba Brazil
| |
Collapse
|
20
|
Veldhuisen B, Porcelijn L, Ellen van der Schoot C, de Haas M. Molecular typing of human platelet and neutrophil antigens (HPA and HNA). Transfus Apher Sci 2014; 50:189-99. [PMID: 24685245 DOI: 10.1016/j.transci.2014.02.014] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Genotyping is an important tool in the diagnosis of disorders involving allo-immunisation to antigens present on the membranes of platelets and neutrophils. To date 28 human platelet antigens (HPAs) have been indentified on six polymorphic glycoproteins on the surface of platelets. Antibodies against HPAs play a role in foetal and neonatal alloimmune thrombocytopenia (FNAIT), post-transfusion purpura (PTP) and refractoriness to donor platelets. The 11 human neutrophil antigens (HNAs) described to date have been indentified on five polymorphic proteins on the surface of granulocytes. Antibodies to HNAs are implicated with foetal and neonatal alloimmune neutropenia (FNAIN), autoimmune neutropenia (AIN) and transfusion related acute lung injury (TRALI). In this report, we will review the molecular basis and techniques currently available for the genotyping of human platelet and neutrophil antigens.
Collapse
Affiliation(s)
- Barbera Veldhuisen
- Sanquin Diagnostic Services, Department of Diagnostic Immunohematology, Amsterdam, The Netherlands; Sanquin Research, Department of Experimental Immunohematology, Amsterdam and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
| | - Leendert Porcelijn
- Sanquin Diagnostic Services, Department of Diagnostic Immunohematology, Amsterdam, The Netherlands
| | - C Ellen van der Schoot
- Sanquin Research, Department of Experimental Immunohematology, Amsterdam and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
| | - Masja de Haas
- Sanquin Diagnostic Services, Department of Diagnostic Immunohematology, Amsterdam, The Netherlands
| |
Collapse
|
21
|
Matsuhashi M, Tsuno NH, Sone S, Mishima Y, Nagura Y, Watanabe-Okochi N, Ikeda T, Kashiwase K, Fukuda S, Iriyama T, Hyodo H, Yamashita T, Kamei Y, Arai S, Minami M, Fujii T, Kurokawa M, Tozuka M, Takahashi K, Santoso S. The role of alloantibodies against human platelet antigen-15 in multiply platelet transfused patients. Transfusion 2013; 54:1093-9. [DOI: 10.1111/trf.12455] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2013] [Revised: 08/05/2013] [Accepted: 08/07/2013] [Indexed: 11/27/2022]
Affiliation(s)
- Mika Matsuhashi
- Department of Transfusion Medicine; The University of Tokyo; Giessen Germany
- Analytical Laboratory Chemistry, Graduate School of Health Care Sciences; Tokyo Medical and Dental University; Tokyo Japan
| | - Nelson H. Tsuno
- Department of Transfusion Medicine; The University of Tokyo; Giessen Germany
| | - Shinji Sone
- Department of Transfusion Medicine; The University of Tokyo; Giessen Germany
| | - Yuko Mishima
- Department of Transfusion Medicine; The University of Tokyo; Giessen Germany
| | - Yutaka Nagura
- Department of Transfusion Medicine; The University of Tokyo; Giessen Germany
| | | | - Toshiyuki Ikeda
- Department of Transfusion Medicine; The University of Tokyo; Giessen Germany
| | - Koichi Kashiwase
- HLA Laboratory; Japanese Red Cross Kanto-Koshinetsu Block Blood Center; Giessen Germany
| | - Shinya Fukuda
- Department of Obstetrics and Gynecology; The University of Tokyo Hospital; Giessen Germany
| | - Takayuki Iriyama
- Department of Obstetrics and Gynecology; The University of Tokyo Hospital; Giessen Germany
| | - Hironobu Hyodo
- Department of Obstetrics and Gynecology; The University of Tokyo Hospital; Giessen Germany
| | - Takahiro Yamashita
- Department of Obstetrics and Gynecology; The University of Tokyo Hospital; Giessen Germany
| | - Yoshimasa Kamei
- Department of Obstetrics and Gynecology; The University of Tokyo Hospital; Giessen Germany
| | - Shunya Arai
- Department of Hematology & Oncology; The University of Tokyo; Giessen Germany
| | - Mutsuhiko Minami
- HLA Laboratory; Japanese Red Cross Kanto-Koshinetsu Block Blood Center; Giessen Germany
| | - Tomoyuku Fujii
- Department of Obstetrics and Gynecology; The University of Tokyo Hospital; Giessen Germany
| | - Mineo Kurokawa
- Department of Hematology & Oncology; The University of Tokyo; Giessen Germany
| | - Minoru Tozuka
- Analytical Laboratory Chemistry, Graduate School of Health Care Sciences; Tokyo Medical and Dental University; Tokyo Japan
| | - Koki Takahashi
- Department of Transfusion Medicine; The University of Tokyo; Giessen Germany
| | - Sentot Santoso
- Immunohematology Research Department; Institute for Clinical Immunology and Transfusion Medicine; Giessen Germany
| |
Collapse
|
22
|
Özbay PÖ, Ekinci T, Yiǧit S, Yavuzcan A, Uysal S, Soylu F, Cakalagaoglu F. Investigation of prognostic significance of CD109 expression in women with vulvar squamous cell carcinoma. Onco Targets Ther 2013; 6:621-7. [PMID: 23776335 PMCID: PMC3681417 DOI: 10.2147/ott.s41069] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
OBJECTIVE The goal of this study was to investigate the between cluster of differentiation 109 (CD109) expression and tumor diameter, invasion depth, tumor grade, presence of lymph-node metastasis, and overall survival in patients with vulvar squamous cell carcinoma, which is the most common type of vulvar cancer. METHOD Twenty-six patients who underwent an operation for vulvar cancer between 1999 and 2009 in our clinic were included in this study. Immunohistochemical staining was performed on formalin-fixed and paraffin-embedded tissue. RESULT Tumor diameter was not found to be significantly associated with CD109 expression, intensity of cytoplasmic staining, or combined score (P = 0.325, P = 0.169, P = 0.352, respectively). Invasion depth and combined score were also not significantly correlated with CD109 expression (P = 0.324 and P = 0.174 respectively). There was a negative correlation between invasion depth and the intensity of cytoplasmic staining (P = 0.042). There was no significant correlation between tumor stage and CD109 expression, the intensity of cytoplasmic staining, and the combined score (P = 0.574, P = 0.389, P = 0.605, respectively). A significant positive correlation was observed between tumor grade and CD109 expression, the intensity of cytoplasmic staining, and the combined score (P = 0.003, P = 0.018, P = 0.008, respectively). No significant difference was found between the percentages of CD109 expression in patients with positive (48%) and negative (11%) lymph nodes (P = 0.058). The percentage of CD109 expression did not significantly differ in relation to overall survival (P = 0.483). CONCLUSION Comprehensive and more extensive studies are needed to examine the relationship between CD109 expression and vulvar malignant lesions.
Collapse
Affiliation(s)
- Pelin Özün Özbay
- Department of Obstetrics and Gynecology, Dogubeyazıt State Hospital, Aǧrı
- Department of Obstetrics and Gynecology, Atatürk Training and Research Hospital, izmir
| | - Tekin Ekinci
- Department of Obstetrics and Gynecology, Atatürk Training and Research Hospital, izmir
- Department of Obstetrics and Gynecology, Kozluk State Hospital, Batman
| | - Seyran Yiǧit
- Department of Pathology, Atatürk Training and Research Hospital, Izmir
| | - Ali Yavuzcan
- Department of Obstetrics and Gynecology, Atatürk Training and Research Hospital, izmir
- Department of Obstetrics and Gynecology, Düzce University Faculty of Medicine, Düzce, Turkey
| | - Selda Uysal
- Department of Obstetrics and Gynecology, Atatürk Training and Research Hospital, izmir
| | - Ferit Soylu
- Department of Obstetrics and Gynecology, Atatürk Training and Research Hospital, izmir
| | | |
Collapse
|
23
|
An QX, Li CY, Xu LJ, Zhang XQ, Bai YJ, Shao ZJ, Zhang W. High-throughput simultaneous genotyping of human platelet antigen-1 to -16 by using suspension array. Transfusion 2013; 53:2722-8. [PMID: 23550657 DOI: 10.1111/trf.12164] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2012] [Revised: 12/15/2012] [Accepted: 01/10/2013] [Indexed: 11/30/2022]
Abstract
BACKGROUND Comprehensive and accurate detection of human platelet antigens (HPAs) plays a significant role in diagnosis and prevention of the platelet (PLT) alloimmune syndromes and ensuring clinical safety of patients undergoing PLT transfusion. The majority of the available methods are incapable of performing high-throughput simultaneous detection of HPA-1 to -16, and the accuracy of many methods needs to be further enhanced. STUDY DESIGN AND METHODS We have developed a new HPA-genotyping method for simultaneous detection of HPA-1 to -16 based on suspension array technology. A total of 216 samples from Chinese Han donors in Xi'an were genotyped using the developed method, and all the samples again were genotyped using polymerase chain reaction (PCR) sequence-based typing (PCR-SBT), which is considered the gold standard. RESULTS All 216 samples were successfully genotyped for HPA-1 to -16 using both our method and PCR-SBT. Results showed that the genotype and allele frequencies obtained using our method were fully consistent with those obtained using PCR-SBT. CONCLUSION Our method provides accurate, high-throughput, and simultaneous genotyping of HPA-1 to -16 and will serve as the foundation for large-scale clinical genotyping of HPAs and for the establishment of an HPA-typed PLT donor registry.
Collapse
Affiliation(s)
- Qun-Xing An
- Department of Blood Transfusion, Xijing Hospital, Xi'an, China; Department of Epidemiology, Faculty of Preventive Medicine, Fourth Military Medical University, Xi'an, China; State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, Fourth Military Medical University, Xi'an, China; Department of Blood Transfusion, Chengdu Military General Hospital, Chengdu, China; Department of Blood Transfusion, 307 Hospital of PLA, Beijing, China
| | | | | | | | | | | | | |
Collapse
|
24
|
Lane-Serff H, Sun Y, Metcalfe P, Wright GJ. Expression of recombinant ITGA2 and CD109 for the detection of human platelet antigen (HPA)-5 and -15 alloantibodies. Br J Haematol 2013; 161:453-5. [PMID: 23406260 DOI: 10.1111/bjh.12252] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
25
|
Human platelet antigen genotyping and expression of CD109 (human platelet antigen 15) mRNA in various human cell types. BIOMED RESEARCH INTERNATIONAL 2013; 2013:946403. [PMID: 23509816 PMCID: PMC3583088 DOI: 10.1155/2013/946403] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/12/2012] [Revised: 01/07/2013] [Accepted: 01/08/2013] [Indexed: 11/17/2022]
Abstract
CD109 gene encodes a glycosylphosphatidylinositol-linked glycoprotein found in a subset of platelets and endothelial cell, and human platelet antigen (HPA) 15 is found on CD109. We evaluated the HPA genotype and/or the CD109 mRNA expression on two peripheral blood stem cells (PBSC), two peripheral bloods (PB), 12 granulocyte products, natural killer (NK)-92, B-lymphocyte (CO88BV59-1), K-562 leukemia cell line, human embryonic stem cell (hESC), and human fibroblasts (HF). HPA genotyping was performed by SNaPshot assay and CD109 mRNA expression was evaluated by real-time PCR with SYBR green and melting curve analysis. Genotype HPA-15a/-15a was found in PBSC#1 and two granulocyte products, and HPA-15a/-15b was found in PBSC#2, eight granulocyte products, NK-92, K-562, hESC, and HF, and HPA-15b/-15b was found in two granulocyte products. CD109 mRNA expression was highly increased in HF and increased in CD34+ and CD34- PBSCs and some granulocyte products, compared to the PB. However, the increase of expression level varied among the PBSC and granulocyte products. The CD109 mRNA expression of NK-92, K-562, hESC, and CO 88BV59-1 was not detected. HPA genotype was evaluated in various cells and the expression of CD109, which contains HPA 15, was different among cell lines and high in HF and PBSCs.
Collapse
|
26
|
Peterson JA, McFarland JG, Curtis BR, Aster RH. Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and management. Br J Haematol 2013; 161:3-14. [PMID: 23384054 DOI: 10.1111/bjh.12235] [Citation(s) in RCA: 97] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Neonatal alloimmune thrombocytopenia, (NAIT) is caused by maternal antibodies raised against alloantigens carried on fetal platelets. Although many cases are mild, NAIT is a significant cause of morbidity and mortality in newborns and is the most common cause of intracranial haemorrhage in full-term infants. In this report, we review the pathogenesis, clinical presentation, laboratory diagnosis and prenatal and post-natal management of NAIT and highlight areas of controversy that deserve the attention of clinical and laboratory investigators.
Collapse
Affiliation(s)
- Julie A Peterson
- Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI 53226-3548, US.
| | | | | | | |
Collapse
|
27
|
Maślanka K, Michur H, Guz K, Wróbel A, Uhrynowska M, Misiak A, Ejduk A, Brojer E, Zupańska B. The relevance of HPA-15 antigen expression for anti-HPA-15 antibody detection. Int J Lab Hematol 2011; 34:65-9. [PMID: 21752233 DOI: 10.1111/j.1751-553x.2011.01358.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
INTRODUCTION The HPA-15 antigen system is characterized by a low antigen expression on platelets. The antibodies against this antigen are implied in fetal/neonatal alloimmune thrombocytopenia (F/NAIT), post-transfusion purpura, and refractoriness to platelet transfusions. Detection of these antibodies appears to be related to the level of HPA-15 expression on the platelets used in the monoclonal antibody-specific immobilization of platelet antigen (MAIPA) assay. METHODS We performed genotyping of 300 healthy blood donors for HPA-15 by TaqMan real-time PCR technology, and the HPA-15 antigen expression was investigated in 13 HPA-15aa and 19 HPA-15bb individuals. We also investigated the relevance of HPA-15 antigen expression on donor platelets used in MAIPA for antibody detection in 223 multitransfused hematological patients and 271 women with suspected F/NAIT. RESULTS In Polish donors, the HPA-15a allele frequencies were lower than the HPA-15b (0.480 vs. 0.515). We identified three HPA-15 expression groups: high (36.7 ± 8.36 MFI - eight cases), medium (19.5 ± 6.2 MFI - 21 cases), and low (6.5 ± 5.9 MFI - three cases). The HPA-15 expression was stable over time. The HPA-15aa and HPA-15bb platelets with high antigen expression were used for anti-HPA-15 antibody detection; anti-HPA-15 antibodies were detected in 4/223 (1.8%) patients receiving multiple transfusions but in none of the 271 women with suspected F/NAIT. Further examination of the four sera by MAIPA with various platelets revealed the optical density in the assay to be closely related to the level of HPA-15 antigen expression. CONCLUSION Anti-HPA-15 antibody detection should be based on carefully selected platelets with high HPA-15 expression level.
Collapse
Affiliation(s)
- K Maślanka
- Institute of Hematology and Transfusion Medicine, Warsaw, Poland
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Hayashi T, Amakishi E, Matsuyama N, Yasui K, Furuta RA, Hori Y, Fukumori Y, Tanaka S, Curtis BR, Inoue M, Hirayama F. Detection of antibodies against human platelet antigens 15a and 15b by using a cell line panel. Br J Haematol 2010; 151:402-4. [PMID: 20812998 DOI: 10.1111/j.1365-2141.2010.08369.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
29
|
Landau M, Rosenberg N. Molecular insight into human platelet antigens: structural and evolutionary conservation analyses offer new perspective to immunogenic disorders. Transfusion 2010; 51:558-69. [PMID: 20804530 PMCID: PMC3084503 DOI: 10.1111/j.1537-2995.2010.02862.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
BACKGROUND Human platelet antigens (HPAs) are polymorphisms in platelet membrane glycoproteins (GPs) that can stimulate production of alloantibodies once exposed to foreign platelets (PLTs) with different HPAs. These antibodies can cause neonatal alloimmune thrombocytopenia, posttransfusion purpura, and PLT transfusion refractoriness. Most HPAs are localized on the main PLT receptors: 1) integrin αIIbβ3, known as the fibrinogen receptor; 2) the GPIb-IX-V complex that functions as the receptor for von Willebrand factor; and 3) integrin α2β1, which functions as the collagen receptor. STUDY DESIGN AND METHODS We analyzed the structural location and the evolutionary conservation of the residues associated with the HPAs to characterize the features that induce immunologic responses but do not cause inherited diseases. RESULTS We found that all HPAs reside in positions located on the protein surface, apart from the ligand-binding site, and are evolutionary variable. CONCLUSION Disease-causing mutations often reside in highly conserved and buried positions. In contrast, the HPAs affect residues on the protein surface that were not conserved throughout evolution; this explains their naive effect on the protein function. Nonetheless, the HPAs involve substitutions of solvent-exposed positions that lead to altered interfaces on the surface of the protein and might present epitopes foreign to the immune system.
Collapse
Affiliation(s)
- Meytal Landau
- Amalia Biron Research Institute of Thrombosis and Hemostasis, Chaim Sheba Medical Center, Tel-Hashomer, Israel
| | | |
Collapse
|
30
|
Jallu V, Dusseaux M, Kaplan C. A new Ser472Asn (Cab2(a+)) polymorphism localized within the αIIb "thigh" domain is involved in neonatal thrombocytopenia. Transfusion 2010; 51:393-400. [PMID: 20723174 DOI: 10.1111/j.1537-2995.2010.02815.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND A new platelet antigen, Cab2(a+), was identified in a case of severe neonatal alloimmune thrombocytopenia (<8 × 10(9)/L) in twins. STUDY DESIGN AND METHODS Coding sequences of αIIb and β3 genes from parents were amplified and sequenced. CHO cell lines expressing wild-type or mutated forms of the complex were established to study the role of the mutation in alloimmunization and in αIIbβ3 functions. RESULTS The father and twins were heterozygous for a single αIIb c.1508G>A mutation leading to a Ser472Asn substitution. Immunologic assays with transfected CHO cells revealed the Asn472 form of αIIbβ3 responsible for the Cab2(a+) epitope but not an Ala472 form. Using these cells lines we demonstrated that both Ser472Asn and Ser472Ala substitutions produced limited structural alteration as revealed by the reactivity of a panel of anti-αIIbβ3 monoclonal antibodies (MoAbs). Activated Asn472 and Ala472 forms of αIIbβ3 supported 1) binding of soluble fibrinogen and of the ligand mimetic MoAb PAC-1, 2) ligand-induced binding site epitopes exposure (MoAbs AP-5 and D3GP3), and 3) cell aggregation. Adhesion onto adsorbed fibrinogen was conserved and was specifically inhibited by MoAb AP-2 or peptide RGDS. Finally outside-in signaling was not affected. CONCLUSION We have characterized a new low-frequency alloantigen (<1%) resulting from the Ser472Asn substitution in αIIb and shown this polymorphism to have a limited effect, if any, on the αIIbβ3 complex functions.
Collapse
|
31
|
Novelli S, Canals C, Nogués N, Julià MR, Gracia M, Vinyets I, Muñiz-Diaz E. Severe neonatal alloimmune thrombocytopaenia with anaemia. Transfus Med 2010; 20:125-6. [DOI: 10.1111/j.1365-3148.2009.00974.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
32
|
Brouk H, Halle L, Bertrand G, Neche FZ, Ouelaa H, Kaplan C. Human platelet antigen allele frequencies in different Algerian populations. ACTA ACUST UNITED AC 2010; 75:673-8. [DOI: 10.1111/j.1399-0039.2009.01429.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
33
|
Matsuhashi M, Tsuno NH, Kawabata M, Yokoyama T, Tazaki Y, Takashima T, Oda H, Kuroda Y, Nagayoshi Y, Morita S, Shibata Y, Santoso S, Takahashi K. The first case of alloantibody against human platelet antigen-15b in Japan: possible alloimmunization by a hydatidiform mole. Transfusion 2009; 50:1126-30. [PMID: 20030792 DOI: 10.1111/j.1537-2995.2009.02537.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND The involvement of the human platelet antigen (HPA)-15 system in neonatal alloimmune thrombocytopenia (NAIT) has been reported in various populations, but not in the Japanese population. In Japan, the mixed passive hemagglutination assay (MPHA) is used for detection of HPA alloantibodies. However, most of the reported cases of HPA-15 incompatibility are based on the monoclonal antibody immobilization of platelet antigen (MAIPA) assay or immunoprecipitation; thus there is a possibility that HPA-15 alloantibodies are not efficiently detected by the MPHA, and currently, the causative antibody is not detectable in approximately half of the suspected NAIT cases in Japan. STUDY DESIGN AND METHODS We examined the sera of mothers from NAIT cases, previously with undetected HPA antibodies by MPHA, using the MAIPA technique. Sera from 90 mothers of suspected NAIT were tested by MAIPA for the presence of anti-HPA-15 alloantibodies. RESULTS Anti-HPA-15b was detected in one case. This case was a mother in the first pregnancy diagnosed as hydatid mole-coexisting fetus, and the baby was born with suspected NAIT. The familial analysis revealed compatibility of HPA-15 genotype between the mother and the baby (both HPA-15a/a), but incompatibility with the paternal one (HPA-15a/b). The hydatid mole's tissue was genotyped as HPA-15b positive. Besides anti-HPA-15b, maternal sera contain strong HLA Class I antibody CONCLUSIONS Here we reported the first case of anti-HPA-15 in Japan. Alloimmunization against the hydatid mole seems to be responsible for the production of HPA-15b alloantibody. This antibody, however, did not apparently involve in the development of NAIT of the newborn, the coexisting anti-HLA Class I being the possible cause.
Collapse
Affiliation(s)
- Mika Matsuhashi
- Department of Transfusion Medicine, The University of Tokyo, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Lucas G, Culliford S, Green F, Sidra G, Calvert A, Green A, Harrison P, Harvey J, Allen D, Smillie D, Masurekar A, Marks D, Russell N, Massey E. Recipient-derived HPA-1a antibodies: a cause of prolonged thrombocytopenia after unrelated donor stem cell transplantation. Transfusion 2009; 50:334-9. [PMID: 19874563 DOI: 10.1111/j.1537-2995.2009.02448.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND Patients with human platelet antigen (HPA) specific antibodies in cases of neonatal alloimmune thrombocytopenia and platelet (PLT) refractoriness derive clinical benefit from the use of HPA-selected PLTs. STUDY DESIGN AND METHODS This study describes three patients with underlying diagnoses of acute myeloid leukemia, chronic lymphocytic leukemia, and myelodysplasia, respectively, who underwent allogeneic bone marrow transplantation (BMT) with unrelated donors matched at the HLA-A, B, C, Dr, and DQ loci but who failed to achieve an adequate PLT count. Investigation using PLT immunofluorescence test, monoclonal antibody immobilization of PLT antigens assay, and genotyping revealed the presence of recipient-derived HPA-1a antibodies. RESULTS In two patients, anti-HPA-1a was detected post-BMT and in the third patient, anti-HPA-1a was detected during pre-BMT chemotherapy. Despite apparent 100% engraftment of donor cells, the patients' PLT counts failed to recover 9-10 months posttransplant. The patients remained PLT-transfusion dependent and failed to achieve satisfactory increments following random donor or HLA-matched PLT transfusions. After the identification of HPA-1a antibodies, the patients were supported by HPA-1a(-) PLTs and satisfactory posttransfusion PLT increments were obtained. These cases illustrate that HPA-1a antibodies may remain detectable for 10 months following apparently successful donor engraftment and the disappearance of recipient-derived HLA antibodies. The prolonged persistence of recipient-derived PLT-specific antibodies following BMT has to our knowledge not been described previously. CONCLUSION HPA-1a antibodies were associated with protracted PLT-transfusion dependence and significant hemorrhagic complications. Appropriate and timely laboratory investigation for HPA-specific antibodies followed by transfusion support with HPA-selected PLTs provided the cornerstone of the hemostatic management in these cases.
Collapse
Affiliation(s)
- Geoff Lucas
- Histocompatibility& Immunogenetics, NHS Blood and Transplant, Northway, Bristol, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Peterson JA, Gitter ML, Kanack A, Curtis B, McFarland J, Bougie D, Aster R. New low-frequency platelet glycoprotein polymorphisms associated with neonatal alloimmune thrombocytopenia. Transfusion 2009; 50:324-33. [PMID: 19821948 DOI: 10.1111/j.1537-2995.2009.02438.x] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND Recent reports suggest that maternal immunization against low-frequency, platelet (PLT)-specific glycoprotein (GP) polymorphisms is a more common cause of neonatal alloimmune thrombocytopenia (NATP) than previously thought. STUDY DESIGN AND METHODS Serologic and molecular studies were performed on PLTs and DNA from three families in which an infant was born with apparent NATP not attributable to maternal immunization against known PLT-specific alloantigens. RESULTS Antibodies reactive only with paternal PLTs were identified in each mother. In Cases 2 (Kno) and 3 (Nos), but not Case 1 (Sta), antibody recognized paternal GPIIb/IIIa in solid-phase assays. Unique mutations encoding amino acid substitutions in GPIIb (Case 2) or GPIIIa (Cases 1 and 3) were identified in paternal DNA and in DNA from two of the affected infants. Antibody from all three cases recognized recombinant GPIIIa (Case 1 [Sta] and Case 3 [Nos]) and GPIIb (Case 2, Kno) mutated to contain the polymorphisms identified in the respective fathers. None of 100 unselected normal subjects possessed the paternal mutations. Enzyme-linked immunosorbent assay and flow cytometric studies suggested that failure of maternal serum from Case 1 (Sta) to react with paternal GPIIIa in solid-phase assays resulted from use of a monoclonal antibody AP2, for antigen immobilization that competed with the maternal antibody for binding to the Sta epitope. CONCLUSION NATP in the three cases was caused by maternal immunization against previously unreported, low-frequency GP polymorphisms. Maternal immunization against low-frequency PLT-specific alloantigens should be considered in cases of apparent NATP not resolved by conventional serologic and molecular testing.
Collapse
Affiliation(s)
- Julie A Peterson
- Blood Research Institute and Platelet & Neutrophil Immunology Laboratory, BloodCenter of Wisconsin, Milwaukee, Wisconsin 53201-2178, USA.
| | | | | | | | | | | | | |
Collapse
|
36
|
Veldhuisen B, van der Schoot CE, de Haas M. Blood group genotyping: from patient to high-throughput donor screening. Vox Sang 2009; 97:198-206. [PMID: 19548962 DOI: 10.1111/j.1423-0410.2009.01209.x] [Citation(s) in RCA: 84] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Blood group antigens, present on the cell membrane of red blood cells and platelets, can be defined either serologically or predicted based on the genotypes of genes encoding for blood group antigens. At present, the molecular basis of many antigens of the 30 blood group systems and 17 human platelet antigens is known. In many laboratories, blood group genotyping assays are routinely used for diagnostics in cases where patient red cells cannot be used for serological typing due to the presence of auto-antibodies or after recent transfusions. In addition, DNA genotyping is used to support (un)-expected serological findings. Fetal genotyping is routinely performed when there is a risk of alloimmune-mediated red cell or platelet destruction. In case of patient blood group antigen typing, it is important that a genotyping result is quickly available to support the selection of donor blood, and high-throughput of the genotyping method is not a prerequisite. In addition, genotyping of blood donors will be extremely useful to obtain donor blood with rare phenotypes, for example lacking a high-frequency antigen, and to obtain a fully typed donor database to be used for a better matching between recipient and donor to prevent adverse transfusion reactions. Serological typing of large cohorts of donors is a labour-intensive and expensive exercise and hampered by the lack of sufficient amounts of approved typing reagents for all blood group systems of interest. Currently, high-throughput genotyping based on DNA micro-arrays is a very feasible method to obtain a large pool of well-typed blood donors. Several systems for high-throughput blood group genotyping are developed and will be discussed in this review.
Collapse
Affiliation(s)
- B Veldhuisen
- Sanquin Research, Amsterdam and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
| | | | | |
Collapse
|
37
|
[Genotyping applied to platelet immunology: when? How? Limits]. Transfus Clin Biol 2009; 16:164-9. [PMID: 19409829 DOI: 10.1016/j.tracli.2009.03.018] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2009] [Accepted: 03/19/2009] [Indexed: 11/21/2022]
Abstract
Platelet alloantigens named Human Platelet Antigens (HPA) are involved in immune conflicts such as post-transfusion purpura, platelet transfusion refractoriness and neonatal alloimmune thrombocytopenia. Biological diagnosis relies on: (1) detection of alloantibodies; (2) identification of the alloantigen involved in the immune conflict. Since the development of methods based on molecular biology, platelet genotyping is preferred to phenotyping. Today, most of the Platelet Immunology Units use PCR-RFLP or PCR-SSP, and few use real-time PCR. An increasing amount of commercial kits based on new technologies is now available, for example microarrays, fluorescent or coloured microbeads, or a combination of both technologies. However, an increasing number of polymorphisms have been discovered that are responsible for erroneous platelet genotypings. Consequently, it would be of interest to develop alternative technologies based on antigen/antibody interaction instead of DNA.
Collapse
|
38
|
Hagiwara S, Murakumo Y, Sato T, Shigetomi T, Mitsudo K, Tohnai I, Ueda M, Takahashi M. Up-regulation of CD109 expression is associated with carcinogenesis of the squamous epithelium of the oral cavity. Cancer Sci 2008; 99:1916-23. [PMID: 19016750 PMCID: PMC11158220 DOI: 10.1111/j.1349-7006.2008.00949.x] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2008] [Revised: 06/09/2008] [Accepted: 06/18/2008] [Indexed: 12/16/2022] Open
Abstract
CD109 is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein whose expression is up-regulated in squamous cell carcinomas (SCCs) of the lung, esophagus, and uterus. The purpose of this study was to evaluate CD109 expression in oral tumors, including premalignant lesions, and to assess the clinical application of CD109 in oral cancer. CD109 expression in oral normal and tumor tissues from 124 patients was examined by immunohistochemical staining with anti-CD109 antibody, and significant relations between clinical features and CD109 expression were statistically assessed. We found that high levels of CD109 expression were frequently detected in SCCs and premalignant lesions of the oral cavity, but not in normal squamous epithelia. The CD109 expression level was higher in well-differentiated SCCs than in poorly differentiated SCCs. Furthermore, premalignant lesions highly expressing CD109 showed higher risk to progress to SCCs. Oral SCC cell lines overexpressing CD109 exhibited accelerated cell growth in vitro compared with control cell lines. In addition, overexpression of CD109 impaired the transforming growth factor (TGF)-beta1-mediated suppression of cell growth. These findings suggest that CD109 plays a role in the development of oral cancers, and is a useful prognostic marker to predict malignant transformation of premalignant lesions.
Collapse
Affiliation(s)
- Sumitaka Hagiwara
- Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | | | | | | | | | | | | | | |
Collapse
|
39
|
De La Vega Elena CD, Nogués N, Fernández Montoya A, Chialina S, Blanzaco PD, Theiller E, Raillon MA, Arancegui N, Solis E, Oyonarte S, Crespo Ferrer V, Campos Muñoz A, Muñiz-Díaz E. Human platelet-specific antigens frequencies in the Argentinean population. Transfus Med 2008; 18:83-90. [DOI: 10.1111/j.1365-3148.2007.00819.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
40
|
Sato T, Murakumo Y, Hagiwara S, Jijiwa M, Suzuki C, Yatabe Y, Takahashi M. High-level expression of CD109 is frequently detected in lung squamous cell carcinomas. Pathol Int 2007; 57:719-24. [PMID: 17922683 DOI: 10.1111/j.1440-1827.2007.02168.x] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
CD109 is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein, which is a member of the alpha2-macroglobulin/C3, C4, C5 family of thioester-containing proteins. It has been reported that CD109 is expressed in a subset of hematopoietic cells, endothelial cells and several kinds of human tumors. Herein it is reported that the CD109 protein is preferentially expressed in lung squamous cell carcinomas compared with other types of lung carcinoma including adenocarcinomas, large cell carcinomas and small cell carcinomas. Immunohistochemical staining of surgically resected lung specimens using an anti-CD109 antibody detected CD109 expression in basal cells of bronchial and bronchiolar epithelia and myoepithelial cells of bronchial secretary glands, but not in bronchial and bronchiolar apical epithelial cells and alveolar epithelial cells. Furthermore, the CD109 immunoreactivity was observed in squamous cell carcinomas at a high frequency compared with other types of lung carcinoma. Although the detailed function of CD109 protein is unclear, these results suggest that CD109 expression may play a role in the development of lung squamous cell carcinoma.
Collapse
Affiliation(s)
- Tomoko Sato
- Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | | | | | | | | | | | | |
Collapse
|
41
|
Ruan L, Pei B, Li Q. Multicolor real-time polymerase chain reaction genotyping of six human platelet antigens using displacing probes. Transfusion 2007; 47:1637-42. [PMID: 17725728 DOI: 10.1111/j.1537-2995.2007.01335.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
BACKGROUND Several genotyping methods for six clinically relevant human platelet antigens (HPAs) have been reported. A four-color real-time polymerase chain reaction (PCR) method using displacing probes for genotyping of the six HPAs is described. STUDY DESIGN AND METHODS Primers and four differently fluorophor-labeled displacing probes were designed and synthesized to detect single-nucleotide polymorphisms responsible for each of the HPA-1, -2, -3, -4, -5, and -15 genotypes. Two HPA systems were analyzed in a single PCR procedure. After validation with samples of known genotypes, a total of 150 blood samples from healthy donors were genotyped. The results were compared with PCR with sequence-specific primers (SSP), PCR-restriction fragment length polymorphism (RFLP), and/or direct DNA sequencing. The frequencies of each HPA allele were calculated. RESULTS Unequivocal real-time PCR genotyping results were obtained with minimal manual manipulation and carryover contamination. All 150 blood samples were correctly genotyped as confirmed by PCR-SSP, PCR-RFLP, and/or direct DNA sequencing. The allelic frequencies of HPA-1 through -5 and -15 among the Chinese population in Xiamen were comparable with those previously reported with Chinese living in other territories. For each specimen, genotyping of all six HPA biallelic systems was achieved in three tubes of PCR within 90 minutes and with material cost of no more than $1. CONCLUSION Genotyping of HPA with real-time PCR using displacing probes is more rapid and reliable compared with PCR-SSP and PCR-RFLP methods and is more affordable than existing real-time PCR-based HPA genotyping assays. Thus, our approach is more suitable for routine HPA analysis and ideal for both urgent clinical testing and high-throughput screening.
Collapse
Affiliation(s)
- Li Ruan
- Molecular Diagnostics Laboratory, Department of Biomedicine, School of Life Sciences, Xiamen University, Xiamen, Fujian, China
| | | | | |
Collapse
|
42
|
Williamson LM, Stainsby D, Jones H, Love E, Chapman CE, Navarrete C, Lucas G, Beatty C, Casbard A, Cohen H. The impact of universal leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusion-associated graft-versus-host disease. Transfusion 2007; 47:1455-67. [PMID: 17655590 DOI: 10.1111/j.1537-2995.2007.01281.x] [Citation(s) in RCA: 71] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND The pathogenesis of posttransfusion purpura (PTP) and transfusion-associated graft-versus-host disease (TA-GVHD) involves patient exposure to donor platelets (PLTs) and T lymphocytes, respectively, which are removed during blood component leukodepletion (LD). STUDY DESIGN AND METHODS Reports of PTP and TA-GVHD to the UK hemovigilance scheme Serious Hazards of Transfusion (SHOT) from 1996 to 2005 were compared before and after implementation of universal LD during 1999. RESULTS There were 45 reports of PTP, with a mean of 10.3 per year before universal LD and 2.3 per year afterward (p < 0.001). All patients had received red cells, but before universal LD, only 1 of 31 (3%) cases had also received PLTs, compared to 8 of 14 (57%) afterward (p < 0.001). Thirty-four cases (76%) had human platelet antigen (HPA)-1a antibodies, whereas 11 had antibodies to other HPA specificities, only 1 of which occurred after LD. Two cases reported before LD also had heparin-dependent PLT antibodies. There were 13 reports of TA-GVHD, all fatal, of which only 2 cases of undiagnosed immunodeficiency met current UK criteria for irradiated components. Eight others had one or more risk factors: B-cell malignancy (6), steroids (1), fresh blood (1), and donor-recipient HLA haplotype share (4). Eleven cases were due to non-LD and 2 to LD components (p < 0.001). No cases have been reported since 2001. In an additional 405 cases, nonirradiated components were transfused in error to high-risk recipients, mainly on fludarabine, but none developed TA-GVHD. CONCLUSIONS These findings suggest that universal LD has further reduced the already low risk of TA-GVHD in immunocompetent recipients and has altered the profile of PTP cases.
Collapse
Affiliation(s)
- Lorna M Williamson
- Department of Haematology, University of Cambridge, and NHS Blood and Transplant, Long Road, Cambridge, United Kingdom.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
|
44
|
Thude H, Schorner U, Helfricht C, Loth M, Maak B, Barz D. Neonatal alloimmune thrombocytopenia caused by human leucocyte antigen-B27 antibody. Transfus Med 2006; 16:143-9. [PMID: 16623921 DOI: 10.1111/j.1365-3148.2006.00634.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Neonatal alloimmune thrombocytopenia (NAIT) occurs when maternal alloantibodies to antigens presented on foetal platelets cause their immune destruction. Whether human leucocyte antigen (HLA) antibodies can cause NAIT is controversial. Here, a patient was described who suffered from a NAIT caused by an HLA-B27 antibody. Sera from the mother and the newborn were tested for human platelet antigen antibodies and HLA antibodies by monoclonal antibody-specific immobilization of platelet antigens (MAIPA) assay, solid phase-linked immunosorbent assay (ELISA), lymphocytotoxicity assay (LCT) and flow cytometric analysis. No antibodies against cluster designation (CD)109 and platelet glycoproteins of the father were found in patient's and mother's serum. However, HLA ELISA was used to identify HLA antibody in both sera. The antibody was specified as HLA-B27 antibody. Typing results showed that the father descended HLA-B27 antigen on patient and his brother. The mother was HLA-B27 negative. It is most conceivable that the previous pregnancy of the mother induced the production of anti-HLA-B27 antibody, which crossed the placenta and subsequently caused an NAIT in the case presented.
Collapse
Affiliation(s)
- H Thude
- Institute for Transfusion Medicine, University Hospital of Jena, Jena, Germany.
| | | | | | | | | | | |
Collapse
|
45
|
Finnson KW, Tam BYY, Liu K, Marcoux A, Lepage P, Roy S, Bizet AA, Philip A. Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes. FASEB J 2006; 20:1525-7. [PMID: 16754747 DOI: 10.1096/fj.05-5229fje] [Citation(s) in RCA: 109] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
We have previously reported that keratinocytes defective in glycosylphosphatidylinositol (GPI)-anchor biosynthesis display enhanced TGF-beta responses. These studies implicated the involvement of a 150 kDa GPI-anchored TGF-beta1 binding protein, r150, in modulating TGF-beta signaling. Here, we sought to determine the molecular identity of r150 by affinity purification and microsequencing. Our results identify r150 as CD109, a novel member of the alpha2-macroglobulin (alpha2M)/complement superfamily, whose function has remained obscure. In addition, we have identified a novel CD109 isoform that occurs in the human placenta but not keratinocytes. Biochemical studies show that r150 contains an internal thioester bond, a defining feature of the alpha2M/complement family. Loss and gain of function studies demonstrate that CD109 is a component of the TGF-beta receptor system, and a negative modulator of TGF-beta responses in keratinocytes, as implicated for r150. Our data suggest that CD109 can inhibit TGF-beta signaling independently of ligand sequestration and may exert its effect on TGF-beta signaling by direct modulation of receptor activity. Together, our results linking CD109 function to regulation of TGF-beta signaling suggest that CD109 plays a unique role in the regulation of isoform-specific TGF-beta signaling in keratinocytes.
Collapse
|
46
|
Tomicic M, Bingulac-Popovic J, Drazic V, Hundric-Haspl Z. Frequency of HPA-15a and HPA-15b (Gov a/b) Human Platelet Alloantigens in the Croatian Population. Arch Med Res 2006; 37:172-4. [PMID: 16314205 DOI: 10.1016/j.arcmed.2005.06.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2005] [Accepted: 06/09/2005] [Indexed: 10/25/2022]
Abstract
BACKGROUND Human platelet antigen (HPA) genotyping is important for epidemiological studies because the prevalence of particular HPA allotypes differs among various populations and plays a major role in the occurrence of HPA alloimmunization. In Caucasians, antibodies to HPA-1a are the most important causes of neonatal alloimmune thrombocytopenia (NATP). Recent studies suggest that anti-HPA 15a/15b (Gov b, Gov a) might be the most likely candidate antibodies following anti-HPA-1a in inducing NATP. METHODS In the present study, HPA-15 system genotype was determined by PCR-SSP method in 279 unrelated subjects from the Croatian population, yielding an HPA-15a and HPA-15b frequency of 0.53 and 0.47, respectively. RESULTS Retrograde testing for the presence of anti-HPA-15 antibodies by use of MAIPA in 39 frozen serum samples from serologically negative cases of clinically suspect NATP produced negative results. CONCLUSION The clinical role of anti-HPA-15 alloantibodies was unable to be confirmed.
Collapse
Affiliation(s)
- Maja Tomicic
- Department of Immunohematology, Croatian Institute of Transfusion Medicine, Zagreb, Croatia.
| | | | | | | |
Collapse
|
47
|
Meyer O, Abou-Chaker K, Heymann G, Bombard S, Kiesewetter H, Salama A. Human platelet antigen genotyping by using sequence-specific primers and the particle gel agglutination assay. Vox Sang 2005; 88:271-4. [PMID: 15877649 DOI: 10.1111/j.1423-0410.2005.00630.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND AND OBJECTIVES Polymerase chain reaction using sequence-specific primers (PCR-SSP) is currently the most widely used technique for human platelet antigen (HPA) genotyping. Here, we describe a novel particle gel-agglutination technique for simplified visualization of the amplified products. MATERIALS AND METHODS Biotinylated primers were used to amplify HPA-1, -2, -3, -4, -5, -6, and -15, and the PCR products were incubated with streptavidin particles. Fluorescein isothiocyanate (FITC)-labelled primers [amplifying a fragment of the human growth hormone (HGH) gene] and anti-FITC-coated particles were used as internal controls. Agglutination of the particles in or on top of the gel indicated specific amplification. A total of 100 samples from blood donors was tested by using this new technique and a standard PCR-SSP protocol. RESULTS The use of biotinylated sequence-specific primers resulted in PCR products that agglutinated streptavidin particles, and the FITC-labelled HGH primers led to agglutination of anti-FITC-coated particles. Negative reactions were clearly distinguishable from positive reactions. The results of the particle gel agglutination method were in concordance with those of the electrophoretic visualization in all cases tested. CONCLUSIONS The new particle agglutination method is reliable and easy to use.
Collapse
Affiliation(s)
- O Meyer
- Charité, Institute of Transfusion Medicine, D-13353 Berlin, Germany
| | | | | | | | | | | |
Collapse
|
48
|
Halle L, Bigot A, Mulen-Imandy G, M'Bayo K, Jaeger G, Anani L, Martageix C, Bianchi F, Julien E, Kaplan C. HPA polymorphism in sub-Saharan African populations: Beninese, Cameroonians, Congolese, and Pygmies. ACTA ACUST UNITED AC 2005; 65:295-8. [PMID: 15730528 DOI: 10.1111/j.1399-0039.2005.00360.x] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
The frequency of human platelet antigen-1 (HPA-1) to HPA-11w (excluding HPA-8w) and HPA-15 systems was studied in four sub-Saharan populations: Beninese, Congolese (Democratic Republic of Congo Kinshasa), Cameroonians, and Aka pygmies (Central African Republic). No report of HPA prevalence has previously been published concerning these populations which are characterized by the highest HPA-2b gene frequencies of any reported to date (Aka 0.393, Benin 0.292, Cameroon 0.237, and Congo 0.224) and at lesser degree HPA-5b (Aka 0.405, Congo 0.268, Cameroon 0.254, and Benin 0.182). This study is of great importance (i) particularly in the context of the diversity caused by the population migrations, we may observe today in our hospitals (ii) to confirm that the Pygmy population with distinctive frequencies (absence of the HPA-1b, HPA-2b, and HPA-5b highest frequencies) is an isolated population.
Collapse
Affiliation(s)
- L Halle
- Institut National de la Transfusion Sanguine, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Bessos H, Wilson DWL, Metcalfe P, Allen D, Urbaniak SJ. Report on the 12th International Society of Blood Transfusion platelet immunology workshop. Vox Sang 2005; 89:105-13. [PMID: 16101693 DOI: 10.1111/j.1423-0410.2005.00672.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND AND OBJECTIVES The aims of the 12th International Society of Blood Transfusion (ISBT) Platelet Immunology Workshop were to evaluate the proficiency of molecular human platelet antigen (HPA) genotyping and detection of platelet antibodies of unusual specificity or reactivity, to assess whether quantification of anti-HPA-1a is practicable, and to determine the variability of reagents and components used in the monoclonal antibody immobilization of platelet antigens assay (MAIPA). MATERIALS AND METHODS Forty participants from 23 countries were sent 10 samples for DNA typing, five samples for antibody detection, a freeze-dried anti-HPA-1a standard, three samples for anti-HPA-1a quantification and a MAIPA method questionnaire. RESULTS The detection and identification of HPA antibodies varied from 2.7 to 95% of participants. The number of HPA genotyping errors per sample ranged from 0 to 3.96% per HPA loci. The majority of laboratories were able to assign an arbitrary number of units/ml of anti-HPA-1a activity to the unknown samples. The MAIPA questionnaire indicated a wide variation among participants, both in method and in reagents used. CONCLUSIONS The results obtained from this workshop highlighted deficiencies in testing regimes and identified a need for internationally available reference materials.
Collapse
Affiliation(s)
- H Bessos
- Scottish National Blood Transfusion Service, Edinburgh, UK.
| | | | | | | | | |
Collapse
|
50
|
Zhang JM, Hashimoto M, Kawai K, Murakumo Y, Sato T, Ichihara M, Nakamura S, Takahashi M. CD109 expression in squamous cell carcinoma of the uterine cervix. Pathol Int 2005; 55:165-9. [PMID: 15826242 DOI: 10.1111/j.1440-1827.2005.01807.x] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
CD109 is a cell surface protein, a member of the alpha(2) macroglobulin/C3,C4,C5 family of thioester-containing proteins. The authors have recently reported that high expression of the CD109 gene was detected in approximately half of the examined lung and esophageal squamous cell carcinomas as well as in the testis, and that CD109 has the characteristics of a cancer-testis antigen. In the present study CD109 expression in cervical squamous cell carcinoma was compared with that in endometrial adenocarcinoma by reverse transcription polymerase chain reaction (RT-PCR). The result demonstrated that CD109 expression is significantly higher in cervical squamous cell carcinomas than in endometrial adenocarcinomas and normal cervix and endometrium. In contrast, when expression of RET finger protein (RFP) and bromodomain testis-specific (BRDT) genes, which are also known to be highly expressed in the testis, was examined, no significant difference in their expression levels was observed between squamous cell carcinomas and adenocarcinomas. These findings suggest that CD109 may become a molecular target for the development of new therapeutics for squamous cell carcinoma of various tissue origins.
Collapse
Affiliation(s)
- Jing-Min Zhang
- Department of Pathology, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | | | | | | | | | | | | | | |
Collapse
|